Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SPK-8011 AAV-mediated Hemophilia A therapy shows stability, durability

Publish date:: July 27, 2020

Key clinical point: SPK-8011 gene therapy for hemophilia A provides stable and durable factor VIII expression with no major safety concerns.

Major finding: FVIII activity was less than 2% before treatment and 5.2%-19.8% at 2 to 3.3 years after treatment.

Study details: A phase 1/2 study of 14 patients.

Disclosures: Spark Therapeutics sponsored the SPK-8011 study. Dr. George disclosed consulting and/or data safety monitoring board activity for Pfizer and AvroBio.

Citation:

George L et al. 2020 ISTH Congress, Abstract OC 03.5.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,